Introduction
============

Uterine adenomyosis is a benign gynecological condition characterized by the ectopic growth of the endometrial tissue, including the endometrial glands and stroma, located at least 2.5 mm below the endometrial-myometrial junction ([@b1-ol-0-0-9082]). The two main forms of adenomyosis are diffuse and focal adenomyoma. Diffuse adenomyosis is more common and characterized by the foci of endometrial mucosa scattered throughout the uterine musculature. Adenomyoma is uncommon, but not rare, and is defined as encapsulated foci including the two glands and stroma implanted within the myometrium ([@b2-ol-0-0-9082]). Adenomyoma is mostly solid and rarely manifests as cystic ([@b2-ol-0-0-9082],[@b3-ol-0-0-9082]). In the majority of cases, the border between the lesion and the surrounding myometrium is not clear. Therefore, the term 'adenomyoma' may be interpreted as grossly circumscribed adenomyotic masses ([@b4-ol-0-0-9082]). Medical therapy for adenomyosis may be effective. Unfortunately, the effects are often transient, and symptoms and signs usually reappear when therapy is stopped ([@b5-ol-0-0-9082]). For decades, hysterectomy was the most popular therapeutic option for patients with symptomatic adenomyosis ([@b6-ol-0-0-9082],[@b7-ol-0-0-9082]). Hysterectomy may be a curative treatment, but it is not acceptable to all women ([@b8-ol-0-0-9082]). Numerous women want alternatives to traditional hysterectomy. However, there are no evidence-based guidelines regarding the appropriate treatment of symptomatic uterine adenomyosis in patients who want to preserve the uterus ([@b5-ol-0-0-9082]). Furthermore, few reports have focused on factors affecting recurrence following laparoscopic adenomyomectomy. The present study aimed to help physicians identify patients with adenomyoma who would benefit from uterus sparing and those who should undergo hysterectomy to avoid a secondary surgery.

Materials and methods
=====================

### Patients

Ethical approval for the collection and publication of patient data was obtained from the institutional review board of Beijing Chao-Yang Hospital of Capital Medical University (Beijing, China; reference no. EC1335097) and written informed consent was obtained from all participating patients. The medical records of 49 female patients (mean age, 40.6±5.2 years; age range, 26--51 years) diagnosed with adenomyoma confirmed by postoperative pathology at Beijing Chao-Yang Hospital of Capital Medical University, admitted between November 2005 and November 2015, were retrospectively reviewed. All inclusion and inclusion criteria are presented in [Fig. 1](#f1-ol-0-0-9082){ref-type="fig"}. The following baseline information was collected: Age, body weight, body height, obstetric history, gynecologic history, smoking history, drinking history, pathological uterine volume (uterus volume was determined by the following formula: a × b × c × π/6, where a, b and c indicate maximum length, width and thickness of the uterus, respectively), serum cancer antigen 125 (CA 125) level, visual analogue scale (VAS) ([@b9-ol-0-0-9082]) score on admission, number of adenomyomas, and other uterine or ovarian pathologies accompanying adenomyosis. All patients received 3-course injections of gonadotropin-releasing hormone agonist (GnRH-a) prior to surgery to reduce the uterine volume and bleeding during surgery. If the patients reported menorrhagia, diagnostic curettage was performed to exclude any malignancy 2 weeks prior to surgery. All patients received transvaginal ultrasound evaluations prior to surgery. An experienced ultrasound doctor was available, however, due to the relatively high cost of the magnetic resonance imaging (MRI), only 14 patients underwent MRI prior to surgery. Representative ultrasound and MRI images of adenomyomas are presented in [Figs. 2](#f2-ol-0-0-9082){ref-type="fig"} and [3](#f3-ol-0-0-9082){ref-type="fig"}.

Patients were asked to specify a VAS score for dysmenorrhea 6 months subsequent to the completion of all therapies. The patients were divided into 3 groups based on this score: Mild or no pain (VAS score 0--2), moderate pain (VAS score 3--6) and severe pain (VAS score 7--10). All patients were followed up at 6 and 12 months subsequent to completing all therapies during a clinical visit. Thereafter, they were followed up at yearly intervals starting from the second year through a phone conversation or outpatient clinic visit, all the patients were followed up till menopause or June 2017 in this article. The endpoint is when the patients entered their menopause. The mean follow-up period was 4.6 years. Reevaluations of the VAS rating and transvaginal ultrasound examination were performed during the outpatient clinic visit if they experienced reappearance or aggravation of dysmenorrhea. As the time when dysmenorrhea relapsed after surgery varied among patients, it was difficult to define a cutoff time for the reappearance of dysmenorrhea the shortest remission period was 7 months, while in some patients it was several years or there was no relapse of dysmenorrhea at all. Recurrence was determined by the subjective VAS score of the patients throughout the follow-up duration following a period of remission from surgery once all other potential causes were excluded. A total of 53 patients fulfilled the inclusion criteria and 4 patients were excluded due to loss to follow-up; therefore, 49 patients were eligible for analysis. Approximately 60% of the leiomyomas and adenomyomas were located at the posterior wall of uterus, 30% were located at the anterior wall and 10% were at the fundus uteri. Tumor position was not included in the present study as it was revealed that relapses did not always appear at the original site where the adenomyosis was removed. Occasionally, relapse occurred on the opposite side of the uterus to where the surgery was performed. It was difficult to identify from where the relapses originated from, particularly for patients with \>1 lesion prior to surgery.

The operative technique involved the recognition of the position of the lesion by careful inspection of the uterus. This is usually difficult and requires adequate experience as the borders of an adenomyoma are not well-defined compared with that of a fibroid ([@b1-ol-0-0-9082]). Then, an incision was created on the uterine wall with monopolar diathermy or tissue scissors. Next, gradual dissection of the adenomyoma was performed with scissors, monopolar diathermy and/or bipolar diathermy without penetrating the endometrium. All recognizable lesions were removed. Surrounding healthy myometrium was removed if necessary. Then, closure of the uterine serosa and myometrium was performed. Finally, intraoperative frozen biopsy was performed to exclude the uterine sarcoma. A total of 8 patients underwent LPSN (Laparoscopic presacral neurectomy) during laparoscopic adenomyomectomy. After identifying the sacral promontory, the peritoneum overlying the sacral promontory was elevated and incised vertically, the retroperitoneal fatty tissue was then removed, the hypogastric plexus was elevated to the lateral side, the nerve fibers are coagulated and excised from the sacral promontory level. The removed nerve tissue was sent for histologic examination.

### Statistical analysis

Data are presented as the mean ± standard deviation. Statistical analyses were conducted using SPSS statistical package for Windows (version 21.0; IBM Corp., Armonk, NY, USA). An unpaired Student\'s t-test and one-way analysis of variance with Fisher\'s Least Significant Difference post hoc test were used to compare continuous variables. Categorical variables were examined using a χ^2^ test and a Kruskal-Wallis test. The optimum cut-off points for CA 125 were determined by the receiver-operating characteristic (ROC) curves for recurrence prediction. Univariate relapse analyses results were evaluated using the Kaplan-Meier method and compared using the log-rank test. Multivariate analyses involving Cox regression models were performed to determine independent factors associated with recurrence. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Prior to surgery, all patients reported severe dysmenorrhea with a VAS score of 9.12±1.05, whereas 16 women had simultaneous menorrhagia. Seven patients were nulliparous, and each of the others experienced only 1 successful birth (except for 1 patient who gave birth twice). The patients had no previous history of gynecological surgery except 13 patients who experienced cesarean deliveries. The preoperative serum CA 125 level was 80.50±56.78 U/ml. Endometriosis was confirmed in 23 patients, and 14 had uterine leiomyoma confirmed by postoperative pathology examination. Eight (16.3%) subjects underwent laparoscopic presacral neurectomy (LPSN) and laparoscopic adenomyomectomy. Twenty-six (53.1%) patients were prescribed 6 months of postoperative GnRH-a therapy. Eight (16.3%) patients were prescribed a levonorgestrel-releasing intrauterine system (LNG-IUS). For patients who selected GnRH-a or LNG-IUS therapy following surgery, the first injection of postoperative GnRH-a was administered immediately following surgery. LNG-IUS was administered at 3--6 months following surgery, depending on the excision extent and depth of the uterine wall, to avoid perforation. Adjuvant treatments were administered according to the patients\' personal preferences. There were no major complications following surgery. Postoperative pain alleviation was evaluated by the patient\'s self-assessment based on abatement of dysmenorrhea at the 6-month follow-up visit. Forty-one patients experienced varying degrees of reduced symptoms of dysmenorrhea, with an overall effectiveness rate of 83.7% (41/49). Twenty-eight (57.1%) patients had mild or no pain subsequent to treatment and had VAS scores ranging between 0 and 2. Menorrhagia improved in 68.8% (11/16) of patients. Associations between potential factors and the mitigation of dysmenorrhea were evaluated by univariate analysis. The p-VAS was significantly different among different groups while no factor was found significantly related to mitigation of dysmenorrhea following resection ([Table I](#tI-ol-0-0-9082){ref-type="table"}).

Dysmenorrhea ratings during the follow-up period are summarized in [Table II](#tII-ol-0-0-9082){ref-type="table"}. Of the 49 patients, 24.5% (12/49) experienced relapse at the end of the follow-up period. The mean diagnosis of recurrence occurred 18.5 ([@b6-ol-0-0-9082]--34) months after resection. Of the 12 patients who relapsed, seven patients were in the mild or no pain group and 5 were in the moderate pain group at 6 months of follow-up. A total of 4 (33.3%) experienced relapse within the first year following treatment, 3 (25%) experienced relapse during the second year and 5 (41.7%) experienced relapse during the third year subsequent to treatment. The VAS score of one patient following the reappearance of dysmenorrhea reached 8, which was higher compared with the preoperative assessment score. The patient underwent uterine artery embolization at Peking Union Medical College Hospital (Beijing, China). The VAS score of another patient increased from 4 to 7 at 17 months following resection; therefore, she underwent a hysterectomy. The degree of pain for the remaining 10 patients experiencing relapse did not reach or exceeded the preoperative level, and they chose oral analgesics when required. Of the 8 patients whose symptoms were not relieved following surgery, 5 were referred for additional surgery (4 hysterectomies and 1 laparoscopic adenomyomectomy). Potential risk factors influencing postoperative recurrence were evaluated by univariate analysis and reported in [Table III](#tIII-ol-0-0-9082){ref-type="table"}. Age at surgery (P=0.017), preoperative serum CA 125 level (P=0.012) and postoperative GnRH-a therapy (P=0.025) were identified as significant risk factors for relapse of dysmenorrhea. Patients in the recurrence group tended to be younger, had higher preoperative serum CA 125 level and fewer of them chose to receive GnRH-a therapy following surgery compared with the recurrence free group.

The optimum cut-off point of the preoperative serum CA 125 level for the prediction of relapse was identified as 46.2 U/ml, with a maximum joint sensitivity of 100% and specificity of 54% using ROC curve analysis ([Fig. 4](#f4-ol-0-0-9082){ref-type="fig"}). Based on this cut-off point, all recurrences were observed for patients with preoperative serum CA 125 levels \>46.2 U/ml, and all recurrent cases had a baseline serum CA 125 level \>46.2 U/ml ([Fig. 5A](#f5-ol-0-0-9082){ref-type="fig"}). Furthermore, 53.1% (26/49) of subjects received 6 courses of postoperative GnRH-a injections as additional therapy; of these, 11.5% (3/26) experienced relapse compared with 39.1% (9/23) of those who did not undergo GnRH-a treatment. Kaplan-Meier curves revealed significant differences (P=0.025) regarding recurrence between GnRH-a injection group and non-GnRH-a injection group ([Fig. 5B](#f5-ol-0-0-9082){ref-type="fig"}). Univariate Kaplan-Meier curves revealed no significant association between accompanying endometriosis or myoma and relapse ([Fig. 5C and D](#f5-ol-0-0-9082){ref-type="fig"}). A Cox proportional hazard model indicated that the preoperative serum CA 125 level \[hazard ratio (HR), 2.356; 95% confidence interval (CI), 1.271--3.570; P=0.011\], postoperative GnRH-a treatment (HR, 0.540; 95% CI, 0.241--0.873; P=0.017) and accompanying endometriosis (HR, 2.182; 95% CI, 1.556--3.031; P=0.003) were significant risk factors associated with dysmenorrhea relapse following laparoscopic adenomyomectomy ([Fig. 6](#f6-ol-0-0-9082){ref-type="fig"}).

Of the 7 nulliparous women, 3 had no desire to have children and 2 underwent *in vitro* fertilization that failed. Two patients (28.6%) became pregnant and experienced successful childbirth during the 2-year follow-up period. Other parous women did not attempt to become pregnant.

Discussion
==========

Adenomyomectomy includes steps similar to those of myomectomy, except that the margin between the tumor and surrounding normal myometrium may not be as substantial as those of myomectomy ([@b10-ol-0-0-9082]). This procedure is suitable for patients presenting with focal-type adenomyosis, which may be relatively clearly separated from adjacent normal tissue. This type of surgery was performed during the present study. Other researchers have attempted modifications including U-shaped suturing, overlapping muscle flap suturing and the triple-flap method ([@b11-ol-0-0-9082]). Cytoreductive surgery involves the excision of diffuse adenomyosis and is similar to the treatment of advanced ovarian cancer types. This procedure is primarily useful when it is difficult to remove all adenomyotic foci ([@b1-ol-0-0-9082]). The boundary between the adenomyoma and myometrium was ill-defined. A recent review indicated that recurrence rates of adenomyosis differed depending on the extent of excision ([@b12-ol-0-0-9082]). Different modifications include the transverse H incision technique, wedge resection of the uterus and asymmetric uterine dissection ([@b13-ol-0-0-9082]--[@b15-ol-0-0-9082]).

There are few reports on the factors that influence the recurrence of adenomyosis. In the present study, it was revealed that patients with adenomyosis with higher CA 125 levels and accompanying endometriosis were more likely to experience the relapse of dysmenorrhea following adenomyomectomy. Preoperative serum CA 125 appeared to be a promising predictor of relapse, with a cut-off value of 46.2 U/ml in the present study. CA 125 is a glycoprotein derived from the embryonic coelomic epithelium and is expressed by certain normal tissue types. High-serum CA 125 has been commonly used as a biomarker for epithelial ovarian cancer ([@b16-ol-0-0-9082],[@b17-ol-0-0-9082]). Increased serum CA 125 serves as a diagnostic tool for screening adenomyosis; however, it lacks specificity in its ability to differentiate adenomyosis from other diseases ([@b18-ol-0-0-9082]). Kil *et al* ([@b16-ol-0-0-9082]) measured serum CA 125 in 2,149 women diagnosed with adenomyosis who underwent total hysterectomy and revealed that it was promising in the differential diagnosis of adenomyosis and leiomyoma at 19 U/ml, with a sensitivity of 66% and specificity of 79.3%. Using 19 U/ml as a reference, there may be a proportion of patients suitable for adenomyomectomy screened with a serum CA level of 46.2 U/ml in clinical practice. Although the mechanism of increased CA 125 is not yet fully understood, inflammatory reactions, peritoneal irritation or peritoneal stretch that alter endothelial permeability may allow CA 125 to reach the circulation, thereby resulting in higher CA 125 concentrations ([@b17-ol-0-0-9082]). In addition, the ectopic endometrium was confirmed to secrete significantly higher CA 125 concentrations compared with the normal endometrium in patients with adenomyosis ([@b18-ol-0-0-9082]). Furthermore, serum levels of CA 125 were higher in moderate to severe cases of endometriosis compared with in mild cases ([@b19-ol-0-0-9082]). A previous study revealed that suppressing CA 125 may suppress the adhesion, invasion and migration of ovarian cancer cells ([@b20-ol-0-0-9082]), thereby implying that CA 125 may facilitate ectopic endometrium migration and adhesion in the surrounding myometrium during adenomyosis development.

Postoperative GnRH-a was identified as an independent factor influencing relapse in the present study. GnRH-a therapy results in the decreased secretion of gonadotropin, which results in the suppression of the hypothalamic-pituitary-gonadal axis and ovarian function, and additionally results in hypoestrogenism, which inhibits the proliferative action of the myometrium ([@b5-ol-0-0-9082]). Entopic and ectopic types of endometria of adenomyosis exhibit a series of molecular and metabolic changes that increase angiogenesis and proliferation, enhance local progesterone resistance and augment estrogen production ([@b7-ol-0-0-9082]). Thereby, increasing infiltration and excessive growth of endometrial stromal cells in the junctional zone facilitates the establishment of adenomyosis ([@b21-ol-0-0-9082]). GnRH-a therapy has been demonstrated to reduce angiogenesis and inflammation and to induce apoptosis in women diagnosed with adenomyosis ([@b21-ol-0-0-9082]). In the present study, 26 of 49 women received 6 courses of GnRH-a therapy; and of this group, 11.5% (3/26) experienced relapse at the end of the follow-up period whereas 39.1% (9/23) experienced relapse in the surgical-only treatment group. Instead of surgery alone, 6 courses of postoperative administration of GnRH-a should be suggested to prevent relapse following adenomyomectomy. It was considered that the development of adenomyosis may be the consequence of interactions between promotive and inhibitive factors. Promotive factors including higher serum CA 125 concentrations, higher estrogen production and resistance to progesterone may facilitate adenomyotic pathological processes including the migration of ectopic endometrium and proliferation of endometrial stromal cells in the junctional zone. Inhibitive factors including GnRH-a therapy and decreased estrogen production prevent this process ([@b7-ol-0-0-9082]). Therefore, it was hypothesized that GnRH-a may curb this process and delay time to recurrence. Relapse may be a matter of time due to exposure to a pathological environment prior to menopause ([@b22-ol-0-0-9082]).

Patients with adenomyosis with accompanying endometriosis compared with patients with accompanying myoma were revealed to be more likely experience relapse in the present study. Endometriosis shares a range of common features with adenomyosis, from clinical manifestations to etiology ([@b7-ol-0-0-9082]). It was hypothesized that they were different forms of the same pathogenesis; however, previous evidence revealed specific distinct pathogenic pathways for adenomyosis, suggesting that they were two different entities ([@b23-ol-0-0-9082]). Compared with adenomyosis, endometriosis appeared to be more frequent in young nulliparous women, but adenomyosis occurred in relatively older and parous women. One previous report states that adenomyosis and deep endometriosis often coexist, particularly in women with infertility or dysmenorrhea ([@b24-ol-0-0-9082]); however, opposing views were held that adenomyosis and deep endometriosis do not necessarily coexist ([@b25-ol-0-0-9082],[@b26-ol-0-0-9082]) and the exact incidence of endometriosis in adenomyosis remains unknown. Eight patients received LPSN during adenomyomectomy in the present study. The relapse rates in the two groups that received or did not receive this procedure were similar, and no significant associations between performing LPSN and relapse of pain were identified. One strategy for treating dysmenorrhea and pelvic pain was to prevent the conduction of pain to the nerve center. Uterine nerve ablation (UNA) and PSN were the two most commonly used procedures. UNA involves cutting the nerves along the uterosacral ligament. Although pelvic endometriosis often coexists with adenomyosis, the efficacy of UNA may decrease over time due to limited denervation ([@b27-ol-0-0-9082]). PSN involves cutting the presacral nerve from the sacral promontory level; therefore, cutting more nerves compared with UNA may be more effective for pain control. Eight patients in the present study underwent PSN during the first several years of the present study. Although PSN and UNA are effective for alleviating pain, technical difficulties and complications arise from affected visceral functions including constipation or urinary urgency. Therefore, these procedures were cautiously applied as adjuvant therapy in the present study.

The present study had a number of limitations. There was the potential for patient selection bias due to the nature of retrospective analysis. Patients with incomplete data were excluded. Not all potentially confounding factors that may have affected the outcomes were obtained from the onset. As a tertiary referral institution, Beijing Chao-Yang Hospital of Capital Medical University admitted patients with relatively complex conditions more easily, whereas other less complicated patients may were referred to other non-tertiary hospitals due to a referral bias. Due to the degree of dysmenorrhea was based on the patient\'s subjective judgment, and therefore differences in the experiences of patients may have affected the results. In addition, a relatively small number of samples and heterogeneity among subjects may have limited the power of the statistical tests, resulting in false conclusions.

In conclusion, adenomyomectomy may be the treatment of choice in patients with adenomyoma who have lower preoperative serum CA 125 levels and without accompanying endometriosis.
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CA 125

:   cancer antigen 125

GnRH-a

:   gonadotropin-releasing hormone agonist

LNG-IUS

:   levonor-gestrel-releasing intrauterine system

LPSN

:   laparoscopic presacral neurectomy

ROC

:   receiver-operating characteristic

UNA

:   uterine nerve ablation

VAS

:   visual analogue scale

![Patient enrollment flowchart. VAS, visual analogue scale.](ol-16-03-3430-g00){#f1-ol-0-0-9082}

![Representative magnetic resonance image of 5 different patients with adenomyoma prior to surgery. Adenomyomas were located at (A) posterior wall and fundus (B) Posterior wall, (C) fundus, (D) anterior wall and fundus and (E) anterior wall.](ol-16-03-3430-g01){#f2-ol-0-0-9082}

![Ultrasound images of one patient with adenomyoma during relapse.](ol-16-03-3430-g02){#f3-ol-0-0-9082}

![ROC curve analysis of the optimum predictive value of CA 125 for relapse. The AUC was 0.786 (95% confidence interval, 0.658--0.914), with a maximum joint sensitivity of 100% and specificity of 54% at 46.2 U/ml. ROC, receiver-operating characteristic; CA 125, cancer antigen 125; AUC, area under curve.](ol-16-03-3430-g03){#f4-ol-0-0-9082}

![Kaplan-Meier curves for time to relapse subsequent to adenomyomectomy. (A) Patients with preoperative serum CA 125 levels ≥46.2 U/ml and \<46.2 U/ml. (B) Patients who did or did not receive GnRH-a therapy postoperatively for 6 months. Patients with accompanying (C) endometriosis or (D) myoma. CA 125, cancer antigen 125; GnRH-a, gonadotropin-releasing hormone agonist.](ol-16-03-3430-g04){#f5-ol-0-0-9082}

![Multivariable Cox regression analysis of risk factors associated with relapse. \*P\<0.05. CI, confidence interval; CA 125, cancer antigen 125; GnRH-a, gonadotropin-releasing hormone agonist.](ol-16-03-3430-g05){#f6-ol-0-0-9082}

###### 

Factors influencing dysmenorrhea relief as determined by p-VAS.

  Variables                                                              No relief (n=8)             Partial relief (n=13)        Near-complete relief (n=28)   P-value
  ---------------------------------------------------------------------- --------------------------- ---------------------------- ----------------------------- ---------
  p-VAS                                                                  9.38±0.74                   4.46±0.97                    0.46±0.69                     \<0.001
  Age (years)                                                            41.4±6.8                    40.6±4.7                     40.3±5.1                      0.884
  Body Mass Index (kg/m^2^)                                              22.3±3.5                    22.8±2.5                     23.1±3.3                      0.831
  Menorrhagia                                                                                                                                                   0.369
    Yes, % (n)                                                           12.5% ([@b2-ol-0-0-9082])   43.8% ([@b7-ol-0-0-9082])    43.8% ([@b7-ol-0-0-9082])     
    No, % (n)                                                            18.2% ([@b6-ol-0-0-9082])   18.2% ([@b6-ol-0-0-9082])    63.6% ([@b21-ol-0-0-9082])    
    Gravidity                                                            1.8±1.0                     1.8±1.0                      2.5±1.0                       0.055
  History of cesarean delivery                                                                                                                                  0.558
    Yes, % (n)                                                           23.1% ([@b3-ol-0-0-9082])   7.7% ([@b1-ol-0-0-9082])     69.2% ([@b9-ol-0-0-9082])     
    No, % (n)                                                            13.9% ([@b5-ol-0-0-9082])   33.3% ([@b12-ol-0-0-9082])   52.8% ([@b19-ol-0-0-9082])    
  Preoperative serum cancer antigen 125 level (U/ml)                     84.9±79.2                   91.6±47.9                    74.1±54.6                     0.647
  Pathological uterine size (cm^3^)                                      127.0±58.2                  145.9±68.3                   145.5±93.1                    0.845
  No of adenomyomas                                                                                                                                             0.919
    Single, % (n)                                                        18.2% ([@b4-ol-0-0-9082])   22.7% ([@b5-ol-0-0-9082])    59.1% ([@b13-ol-0-0-9082])    
    Multiple, % (n)                                                      14.8% ([@b4-ol-0-0-9082])   29.6% ([@b8-ol-0-0-9082])    55.6% ([@b15-ol-0-0-9082])    
  Coexisting endometriosis                                                                                                                                      0.203
    Yes, % (n)                                                           8.7% ([@b2-ol-0-0-9082])    26.1% ([@b6-ol-0-0-9082])    65.2% ([@b15-ol-0-0-9082])    
    No, % (n)                                                            23.1% ([@b6-ol-0-0-9082])   26.9% ([@b7-ol-0-0-9082])    50.0% ([@b13-ol-0-0-9082])    
  Accompanying uterine leiomyoma                                                                                                                                0.344
    Yes, % (n)                                                           14.2% ([@b2-ol-0-0-9082])   42.9% ([@b6-ol-0-0-9082])    42.9% ([@b6-ol-0-0-9082])     
    No, % (n)                                                            17.1% ([@b6-ol-0-0-9082])   20.0% ([@b7-ol-0-0-9082])    62.9% ([@b22-ol-0-0-9082])    
  Laparoscopic presacral neurectomy                                                                                                                             0.796
    Yes, % (n)                                                           12.5% ([@b1-ol-0-0-9082])   37.5% ([@b3-ol-0-0-9082])    50.0% ([@b4-ol-0-0-9082])     
    No, % (n)                                                            17.1% ([@b7-ol-0-0-9082])   24.4% ([@b10-ol-0-0-9082])   58.5% ([@b24-ol-0-0-9082])    
  Postoperative gonadotropin-releasing hormone agonist therapy                                                                                                  0.566
    Yes, % (n)                                                           19.2% ([@b5-ol-0-0-9082])   26.9% ([@b7-ol-0-0-9082])    53.9% ([@b14-ol-0-0-9082])    
    No, % (n)                                                            13.0% ([@b3-ol-0-0-9082])   26.1% ([@b6-ol-0-0-9082])    60.9% ([@b14-ol-0-0-9082])    
  Postoperative levonorgestrel-releasing intrauterine system treatment                                                                                          0.503
    Yes, % (n)                                                           25% ([@b2-ol-0-0-9082])     0% (0)                       75% ([@b6-ol-0-0-9082])       
    No, % (n)                                                            14.6% ([@b6-ol-0-0-9082])   31.7% ([@b13-ol-0-0-9082])   53.7% ([@b22-ol-0-0-9082])    

Data are presented as mean ± standard deviation. p-VAS, postoperative visual analogue scale.

###### 

Dysmenorrhea rating during the follow up period.

                                  Groups (no. of patients)        
  -------------- ---- ----------- -------------------------- ---- ----
  Preoperative   49   9.12±1.05   0                          0    49
  6              49   2.98±3.42   28                         13   8
  12             49   3.16±3.27   25                         15   9
  24             44   3.32±3.38   21                         15   8
  36             35   4.11±3.54   13                         13   9
  48             30   3.97±3.41   11                         13   6
  60             22   3.77±3.18   8                          11   3
  72             12   3.33±2.64   4                          7    1
  84             8    4.38±2.13   1                          6    1
  96             5    5.20±1.48   0                          4    1
  108            2    4.00±1.41   0                          2    0
  120            1    5           0                          1    0

Data are presented as the mean ± standard deviation.

###### 

Univariate analysis of variables influencing recurrence in enrolled patients.

  Characteristics                                                        No recurrence (n=37)         Recurrence (n=12)            P-value
  ---------------------------------------------------------------------- ---------------------------- ---------------------------- ----------------------------------------------------
  Age (years)                                                            41.6±5.2                     37.5±4.1                     0.017^[a](#tfn4-ol-0-0-9082){ref-type="table-fn"}^
  Body mass index (kg/m^2^)                                              23.1±2.7                     22.1±4.1                     0.302
  Menorrhagia                                                                                                                      0.315
    Yes, % (n)                                                           25% ([@b2-ol-0-0-9082])      53.8% ([@b7-ol-0-0-9082])    
    No, % (n)                                                            75% ([@b6-ol-0-0-9082])      46.2% ([@b6-ol-0-0-9082])    
    Gravidity                                                            2.1±1.0                      2.4±1.1                      0.393
  History of cesarean delivery                                                                                                     0.999
    Yes, % (n)                                                           37.5% ([@b3-ol-0-0-9082])    7.7% ([@b1-ol-0-0-9082])     
    No, % (n)                                                            62.5% ([@b5-ol-0-0-9082])    92.3% ([@b12-ol-0-0-9082])   
  Preoperative serum cancer antigen 125 level (U/ml)                     69.0±54.3                    115.8±51.0                   0.012^[a](#tfn4-ol-0-0-9082){ref-type="table-fn"}^
  Pathological uterine size (cm^3^)                                      135.4±84.0                   164.5±70.1                   0.285
  No of adenomyomas                                                                                                                0.683
    Single, % (n)                                                        72.7% ([@b16-ol-0-0-9082])   27.3% ([@b6-ol-0-0-9082])    
    Multiple, % (n)                                                      77.8% ([@b21-ol-0-0-9082])   22.2% ([@b6-ol-0-0-9082])    
  Coexisting endometriosis                                                                                                         0.363
    Yes, % (n)                                                           69.6% ([@b16-ol-0-0-9082])   30.4% ([@b7-ol-0-0-9082])    
    No, % (n)                                                            80.8% ([@b21-ol-0-0-9082])   19.2% ([@b5-ol-0-0-9082])    
  Accompanying uterine leiomyoma                                                                                                   0.156
    Yes, % (n)                                                           92.9% ([@b13-ol-0-0-9082])   7.1% ([@b1-ol-0-0-9082])     
    No, % (n)                                                            68.6% ([@b24-ol-0-0-9082])   31.4% ([@b11-ol-0-0-9082])   
  Laparoscopic presacral neurectomy                                                                                                0.999
    Yes, % (n)                                                           75% ([@b6-ol-0-0-9082])      25% ([@b2-ol-0-0-9082])      
    No, % (n)                                                            75.6% (31)                   24.4% ([@b10-ol-0-0-9082])   
  Postoperative gonadotropin-releasing hormone agonist therapy                                                                     0.025^[a](#tfn4-ol-0-0-9082){ref-type="table-fn"}^
    Yes, % (n)                                                           88.5% ([@b23-ol-0-0-9082])   11.5% ([@b3-ol-0-0-9082])    
    No, % (n)                                                            60.9% ([@b14-ol-0-0-9082])   39.1% ([@b9-ol-0-0-9082])    
  Postoperative levonorgestrel-releasing intrauterine system treatment                                                             0.190
    Yes, % (n)                                                           100% ([@b8-ol-0-0-9082])     0% (0)                       
    No, % (n)                                                            78.4% (29)                   21.6% ([@b12-ol-0-0-9082])   

Data are presented as the mean ± standard deviation.

P\<0.05.
